Mereo BioPharma (MREO) Total Non-Current Liabilities (2017 - 2026)

Mereo BioPharma (MREO) has 10 years of Total Non-Current Liabilities data on file, last reported at $6.5 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $6.5 million, down 19.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.5 million (down 19.71% YoY), and the FY2025 annual result was $5.0 million, down 66.59% from the prior year.
• Total Non-Current Liabilities climbed to $6.5 million in Q1 2026 per MREO's latest filing, from $5.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $16.6 million in Q2 2024 and troughed at $1.8 million in Q4 2022.
• A 5-year average of $10.1 million and a median of $8.3 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities sank 94.84% in 2022, then jumped 764.8% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $1.8 million in 2022, then jumped by 764.8% to $15.6 million in 2023, then declined by 4.46% to $14.9 million in 2024, then tumbled by 66.59% to $5.0 million in 2025, then surged by 31.61% to $6.5 million in 2026.
• Business Quant data shows MREO's Total Non-Current Liabilities at $6.5 million in Q1 2026, $5.0 million in Q4 2025, and $6.4 million in Q3 2025.